DENVER, Aug. 10, 2012 /PRNewswire/ -- Accelr8 Technology
Corp. (NYSE MKT: AXK) today announced that it has named
Steve Reichling as Chief Financial
Officer.
Reichling joins Accelr8 from Roche Tissue Diagnostics where he
served as general manager of its antibody R&D and research
products subsidiary, Spring Bioscience Corp. Prior to this role he
held various finance, accounting and operations leadership roles at
Roche Tissue Diagnostics and Ventana Medical Systems including
director of finance and operations, manager of business development
finance, and head of Internal Audit and Sarbanes Oxley Compliance.
Prior to his tenure at Roche Tissue Diagnostics and Ventana Medical
Systems, Reichling was a life sciences company auditor at Ernst
& Young LLP. He holds a B.A. in accounting and entrepreneurship
from the University of Arizona and is a
Certified Public Accountant.
"We are delighted to welcome Steve to the Accelr8 leadership
team," said John Patience, Accelr8's
Chairman of the Board. "Steve's finance and accounting expertise
and broad business skill set will be invaluable in helping us
realize the potential of Accelr8's technologies."
"I am excited to be joining such a promising diagnostics company
at this important time in its development," said Reichling.
"Accelr8 promises to deliver substantial improvements to patient
care and I am looking forward to working with the team to bring
this revolutionary technology to market."
About Accelr8
Accelr8 Technology Corp. (www.accelr8.com) is a developer
of innovative materials and instrumentation for advanced
applications in medical instrumentation, basic research, drug
discovery, and bio-detection. Accelr8 is developing a rapid
analytical platform for infectious pathogens, the
BACcel™ system, based on its innovative assay
processing and detection technologies. In addition, Accelr8
licenses certain of its proprietary technology for use in
applications outside of Accelr8's own products.
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
SOURCE Accelr8 Technology Corp.